Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae Source: Eur Respir J 2006; 27: 1020-1025 Year: 2006
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Resistance of Streptococcus pneumoniae to penicillin, azitromycin, ciprofloxacyn and ceftriaxon Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001
Long-term, low-dose azithromycin treatment reduces the prevalence of staphylococcus aureus , but selects for macrolide resistance in Danish CF-patients Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002
Clinical efficacy of arbekacin on MRSA pneumonia by intramuscularly injection Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia Source: Eur Respir J 2010; 36: 969-971 Year: 2010
Effectiveness and safety of gatifloxacin in patients with drug resistance tuberculosus befor unsuccessfully treated with ofloxacin and ciprofloxacin Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Activity of N-acetylcysteine in combination with colistin against a collection of colistin resistant Acinetobacter baumannii clinical isolates Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013
Telavancin vs. linezolid in an animal model of severe MRSA pneumonia Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004
Increasing global resistance to penicillin, macrolides and other antimicrobials among isolates of Streptococcus pneumoniae : susceptibility data from three years of the PROTEKT surveillance study Source: Eur Respir J 2003; 22: Suppl. 45, 486s Year: 2003